EP0752880A4 - Treatment of autoimmune disease using oral tolerization and/or type i interferon - Google Patents

Treatment of autoimmune disease using oral tolerization and/or type i interferon

Info

Publication number
EP0752880A4
EP0752880A4 EP95916183A EP95916183A EP0752880A4 EP 0752880 A4 EP0752880 A4 EP 0752880A4 EP 95916183 A EP95916183 A EP 95916183A EP 95916183 A EP95916183 A EP 95916183A EP 0752880 A4 EP0752880 A4 EP 0752880A4
Authority
EP
European Patent Office
Prior art keywords
interferon
treatment
type
autoimmune disease
oral tolerization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95916183A
Other languages
German (de)
French (fr)
Other versions
EP0752880A1 (en
Inventor
David A Hafler
Howard L Weiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of EP0752880A1 publication Critical patent/EP0752880A1/en
Publication of EP0752880A4 publication Critical patent/EP0752880A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rehabilitation Therapy (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
EP95916183A 1994-04-08 1995-04-07 Treatment of autoimmune disease using oral tolerization and/or type i interferon Withdrawn EP0752880A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22537294A 1994-04-08 1994-04-08
US225372 1994-04-08
PCT/US1995/004120 WO1995027499A1 (en) 1994-04-08 1995-04-07 Treatment of autoimmune disease using oral tolerization and/or type i interferon

Publications (2)

Publication Number Publication Date
EP0752880A1 EP0752880A1 (en) 1997-01-15
EP0752880A4 true EP0752880A4 (en) 2000-08-09

Family

ID=22844605

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95916183A Withdrawn EP0752880A4 (en) 1994-04-08 1995-04-07 Treatment of autoimmune disease using oral tolerization and/or type i interferon

Country Status (9)

Country Link
EP (1) EP0752880A4 (en)
JP (1) JPH09511745A (en)
AU (1) AU686797B2 (en)
BR (1) BR9507451A (en)
CA (1) CA2185353A1 (en)
HU (1) HUT74900A (en)
IL (1) IL113303A0 (en)
NO (1) NO964199D0 (en)
WO (1) WO1995027499A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5906816A (en) * 1995-03-16 1999-05-25 University Of Florida Method for treatment of autoimmune diseases
US6372206B1 (en) * 1989-03-02 2002-04-16 University Of Florida Orally-administered interferon-TAU compositions and methods
EP0787147A1 (en) * 1994-10-25 1997-08-06 Immulogic Pharmaceutical Corporation Compositions and treatment for multiple sclerosis
EE04223B1 (en) * 1996-12-24 2004-02-16 Biogen, Incorporated Interferon is a stable liquid formulation containing amino acids
IL126714A (en) * 1997-02-28 2010-12-30 Enzo Therapeutics Inc Use of cells, organs or components thereof for the preparation of a pharmaceutical composition for establishing selective immune downregulation
ES2382488T3 (en) 1997-03-21 2012-06-08 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for diseases mediated by sensitized t cells comprising an il-6 antagonist as an active ingredient
US6812205B2 (en) 2000-03-15 2004-11-02 The Brigham & Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
AU2001264813B2 (en) 2000-05-24 2005-12-08 The United States Of America, As Represented By Secretary Of The Department Of Health And Human Services Methods for preventing strokes by inducing tolerance to e-selectin
JPWO2004058295A1 (en) * 2002-12-26 2006-04-27 第一アスビオファーマ株式会社 Treatment for pemphigoid
WO2008130382A2 (en) 2006-10-31 2008-10-30 East Carolina University Fusion proteins comprising an anti -inflammatory cytokine and an antigen for treatment of immune disorders
EP3348275A3 (en) * 2009-03-31 2018-10-24 East Carolina University Cytokines and neuroantigens for treatment of immune disorders
JP6590330B2 (en) * 2013-11-11 2019-10-16 キッコーマン株式会社 Oral immune tolerance enhancing substance screening method and oral immune tolerance enhancing composition
GB201904767D0 (en) 2019-04-04 2019-05-22 Orexo Ab New pharmaceutical compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0325471A1 (en) * 1988-01-22 1989-07-26 Collagen Corporation Method for suppressing the growth of normal and cancer cells
WO1993016724A1 (en) * 1992-02-28 1993-09-02 Autoimmune, Inc. Bystander suppression of autoimmune diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0325471A1 (en) * 1988-01-22 1989-07-26 Collagen Corporation Method for suppressing the growth of normal and cancer cells
WO1993016724A1 (en) * 1992-02-28 1993-09-02 Autoimmune, Inc. Bystander suppression of autoimmune diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9527499A1 *

Also Published As

Publication number Publication date
WO1995027499A1 (en) 1995-10-19
NO964199L (en) 1996-10-03
AU686797B2 (en) 1998-02-12
JPH09511745A (en) 1997-11-25
EP0752880A1 (en) 1997-01-15
CA2185353A1 (en) 1995-10-19
NO964199D0 (en) 1996-10-03
IL113303A0 (en) 1995-07-31
HUT74900A (en) 1997-02-28
AU2277695A (en) 1995-10-30
BR9507451A (en) 1997-08-05
HU9602750D0 (en) 1996-11-28

Similar Documents

Publication Publication Date Title
GB9609932D0 (en) Use of IL-12 and IFN alpha for the treatment of infectious diseases
ZA907564B (en) Treatment of conditions and disease
EP0994717A4 (en) Treatment of autoimmune disease using tolerization in combination with methotrexate
HU9602750D0 (en) Treatment of autoimmune disease using oral tolerization and/or type i interferon
IL113301A0 (en) Treatment of autoimmune disease using oral tolerization and/or TH2-enhancing cytokines
EP1030663A4 (en) Treatment of fibromyalgia and related disorders
HUP9900147A3 (en) Therapeutic agents and autoimmune diseases
GB9419553D0 (en) Polypeptides and their use in the treatment of auto-immune disease
HUP0003244A2 (en) Novel triptolide derivatives useful in the treatment of autoimmune diseases and pharmaceutical compositions thereof
HUP9800829A3 (en) Collagen-based methods and formulations for the treatment of immune system-mediated diseases
PL322002A1 (en) Variants of human dnase i
GB9611500D0 (en) Prevention and treatment of oral conditions with peptides having anti-adherence activity
IL112681A0 (en) Opioid peptides for the treatment of pain and use thereof
EP0833641A4 (en) Treatment and prevention of prostatic disease
EP0540575A4 (en) Human meg-csf protein and methods
GB9516572D0 (en) Prevention and/or treatment of disease
NZ277605A (en) Human stanniocalcin-alpha polypeptide and dna (rna) encoding polypeptide; polypeptide may be derived from atcc 75861
IL115017A0 (en) Methods of maintaining teeth and oral bone
ZA97210B (en) Oral administration of effective amunts of forms of hyaluronic acid
EG20171A (en) Treatment of conditions and disease
ZA951440B (en) Novel opiold peptides for the treatment of pain and use thereof
PL342649A1 (en) Prevention of amyloidogenous diseases and treatment of them
GB9419549D0 (en) Polypeptides and their use in the treatment of auto-immune disease
AU3163795A (en) Treatment of autoimmune diseases
BG99596A (en) Preparation for the treatment of gums and teeth

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960912

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20000627

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 38/17 A, 7A 61K 38/28 B, 7A 61K 38/39 B, 7A 61K 38/26 B, 7A 61K 38/21 B, 7A 61K 38/21 J, 7A 61K 38:26 J, 7A 61K 38:28 J, 7A 61K 38:39 J

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20000915